Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer

NCT03933319 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: pegylated liposomal doxorubicin

Sponsor

Chinese Academy of Medical Sciences

Collaborators

[object Object]